An Roinn Sláinte
Department of Health
Office of the Chief Medical Officer

Epidemiological report
2nd December 2022

Executive Summary

- The overall epidemiological situation in Ireland indicates that the number of reported and detected infections has increased, while the total number of hospitalised COVID-19 cases and the daily average number of newly confirmed cases in hospital have also slightly increased.
- The total number of confirmed cases in critical care has been broadly stable.
- The number of notified outbreaks has been broadly stable across key vulnerable settings.
- COVID-19 mortality has remained broadly stable, although it is noted that there can be a lag in reporting of deaths.
- SARS-CoV-2 variants continue to be closely monitored and assessed for any potential threat to population health. The World Health Organization (WHO) and the European Centre for Disease Prevention and Control (ECDC) continue to monitor a number of emerging SARS-CoV-2 variants including BQ.1 (and its sub-lineages) and XBB (a recombinant variant).
- The European Centre for Disease Prevention and Control (ECDC) has reported that (1st December 2022), as of epidemiological weeks 45 to 46 (7th November to 20th November 2022), BQ.1 has become the dominant variant in a number of European Union (EU)/European Economic Area (EEA) countries but high prevalence of BQ.1 does not appear to be associated with a deterioration of the epidemiological situation. Some of the countries in which BQ.1 is dominant are among those showing recent increases in transmission and/or severity indicators, but the countries with the highest reported proportions of BQ.1 have not reported any concerning epidemiological changes to date.
- The circulation of SARS-CoV-2 variants (including BQ.1 and BQ.1.1) in Ireland continues to be closely monitored. As in a number of other European countries, the proportion of BQ.1 variant (and its sub-lineages) identified amongst cases sequenced in Ireland has increased. BQ.1 variant (including its lineages) represents in excess of 50% of reported sequenced cases with a specimen collection date in recent epidemiological weeks. The increase in circulation of BQ.1 (and its sub-lineages) in Ireland may contribute to an increase in COVID-19 cases and hospitalisations in the coming weeks and months.

It remains important to provide clear guidance and communication with the public on the evolving disease profile and a cultural shift towards embedding individual and collective personal behaviours to mitigate against COVID-19 and other respiratory infections. It is important that the existing key public health advice continues to be communicated to the general public so that individuals may optimally protect themselves from severe health outcomes associated with COVID-19. It is particularly important that eligible groups for primary and booster doses (first, second and third) continue to be encouraged to avail of vaccination in order to confer optimal protection against the risk of severe disease as well as against other potential long-term consequences of infection.

The current key public health advice is as follows:

Bloc 1, Plaza Míseach, 50 - 58 Sráid Bhagóid Íochtarach, Baile Átha Cliath 2, D02 XW14
Block 1, Miesian Plaza, 50 - 58 Lower Baggot Street, Dublin 2, D02 XW14
T +353 1 635 4251 | info@health.gov.ie
www.health.gov.ie

- Anyone who has symptoms of COVID-19 should self-isolate until 48 hours after symptoms have substantially or fully resolved – please do not attend any social events, work, school or college if you have symptoms.

- Anyone diagnosed with COVID-19 should self-isolate for 7 days from date of onset of symptoms, or if asymptomatic, date of first positive test. Anyone exiting self-isolation at day seven should continue to adhere to other public health protective measures.

- Mask wearing is advised on public transport and in healthcare settings. Mask wearing is also advised based on individual risk assessment. Anyone who wishes to wear a mask should not be discouraged from doing so. Individuals who are vulnerable to COVID-19 are further advised to be aware of the risk associated with activities they may choose to engage in and to take measures to optimally protect themselves. Vulnerable individuals are advised to consider wearing masks in crowded indoor settings, such as may relate, for example, to social gatherings or other activities and events.

- Continue to practise good hand and respiratory hygiene by washing and sanitising hands regularly and coughing/sneezing into your elbow. Maintain a physical distance where possible.

- Meet up outdoors if possible. When meeting indoors, avoid poorly ventilated spaces and keep windows open if possible.

- Many people who were infected with COVID-19 in late 2021 and earlier in 2022 will now be eligible for a booster dose of COVID-19 vaccine. Book a first booster appointment on www.hse.ie if you are 12 years or older. People aged 50 years to 64 years, pregnant women (from 16 weeks), healthcare workers, people aged 12 or older with a condition that puts them at high risk of serious illness from COVID-19 (for example, diabetes or heart disease) are now eligible to register for their second COVID-19 booster vaccine. People aged 65 years or older and people aged 12 or older who have a weak immune system are now eligible to register for their third booster dose. It is not too late to receive a primary course of COVID-19 vaccine. Vaccines remain the most effective way of protecting ourselves from the worst effects of COVID-19.

Epidemiological update

- A total of 1,723 confirmed PCR cases have been reported in the 7 days to 29th November 2022 (cases notified to midnight 28th November 2022), which is a 19% increase from last week when 1,444 PCR positive cases were reported in the 7 days to 22nd November.
- There were 3,610 positive antigen test results reported in the 7 days to 29th November 2022 (results uploaded to HSE portal in the week to 28th November), which is a 26% increase from last week when 2,873 positive antigen test results were reported in the 7 days to 22nd November 2022.
- As of 29th November 2022, the 14-day incidence rate (PCR) per 100,000 population is 67 which is 2% higher than a week previously (65). Incidence rates are likely to be underestimates.
- Nationally, the 7-day incidence (PCR) per 100,000 population as a proportion of 14-day incidence (PCR) per 100,000 population is 54%, demonstrating that there were more confirmed cases identified through PCR testing in laboratories in the 7 days to 29th November, compared with the preceding 7 days.
- The 5-day rolling average of daily reported cases (PCR) is 215 as of 29th November, which is 24% higher than that reported on 22nd November (173).
- Regarding national SARS-CoV-2 wastewater surveillance, in week 47 (to 26th November), of the 65 catchment areas for which a change from the previous week could be calculated, the viral load remained stable (within +/- 10%) in 46 of them, while 13 experienced decreases of 10% or more, and 6 saw increases from 10 to 50%. When data across catchments areas was pooled and normalised for the population, the weekly distribution of SARS-CoV-2 viral load was declining across several catchment areas in recent weeks.
- There were 346 confirmed COVID-19 cases in hospital this morning (2nd December 2022), compared with 318 last week on 25th November. There have been 56 newly confirmed cases in hospital in the 24 hours preceding this morning. On average, there have been 52 new COVID-19 hospitalisations per day observed in the seven days to 2nd December.
- As of 29th November, 38% (N=169) of hospitalised cases were categorised as hospitalised for COVID-19, with the remaining 62% (N=282) categorised as asymptomatic COVID-19 cases and potentially infectious.
- The age breakdown of cases hospitalised for COVID-19 (N=169) as of 29th November: 118 (70%) aged 65 years and older, 32 (19%) aged 50-64, 13 (8%) aged 15-49 and 6 (4%) aged 0-14 years old.
- The vaccination profile of cases aged 15 years and older hospitalised for COVID-19 (N=163) was:
    - Of those aged 65 years and older (N=118): 47% had received a second booster; 29% had received a first booster; and 24% had not completed a primary vaccination course.
    - Of those aged 50-64 (N=32): 22% had received a second booster; 25% had received a first booster; 9% had completed primary vaccination; and 44% had not completed a primary vaccination course.
    - Of those aged 15-49 (N=13): 23% had received a first booster; 8% had completed primary vaccination; and 62% had not completed a primary vaccination course.
- There were 14 confirmed cases in critical care as of this morning (2nd December 2022), compared with 11 a week ago (25th November). There were 2 new admissions to critical care in the 24 hours preceding this morning. On average, there has been approximately 2 new COVID-19 admissions per day observed in the seven days to 2nd December. Of the 14 cases in critical care this morning, 2 were invasively ventilated.

- The number of COVID-19 cases in ICU whose primary reason for admission to ICU was COVID-19 was 3 on 29th November, a decrease from 4 a week previously on 22nd November. The proportion of COVID-19 cases in ICU for whom the primary reason for admission to ICU was COVID-19 decreased from 33% on 22nd November to 25% on 29th November.
- According to National Office of Clinical Audit (NOCA) data, as of 29th November 2022, where vaccination status was known (N=12), no COVID-19 case in ICU was unvaccinated. Of those COVID-19 cases in ICU who had completed their primary course of vaccination (N=12), 67% were recorded as having received a booster/additional dose.
- As of 29th November, 141 patients were in receipt of non-invasive ventilation/Continuous Positive Airway Pressure (CPAP) or High-Flow Oxygen in non-critical care settings, of whom 20 patients were COVID-19 cases.
- There continues to be a significant number of cases of hospital acquired infection (note this is based on data to the week ending 20th November 2022). There were 129 hospital acquired COVID-19 infections reported in the week ending 20th November, compared to 126 in the week ending 13th November, and 112 in the week ending 6th October.
- As of 29th November 2022, there have been 8,197 COVID-19 related deaths reported in Ireland since the outset of the pandemic. As of midnight 29th November 2022, there have been 49 COVID-19 related deaths notified which occurred in November 2022, 119 which occurred in October 2022, and 62 which occurred in September 2022.
- As of 19th November 2022, the HPSC has reported that 967 cases of BQ.1 and its sub-lineages have been detected in Ireland through whole genome sequencing. The proportion of BQ.1 variant (and its sub-lineages) identified amongst cases sequenced in Ireland has increased. BQ.1 variant (including its lineages) represents in excess of 50% of reported sequenced cases with a specimen collection date in recent epidemiological weeks in Ireland. In addition, as of 19th November, 46 cases of Omicron recombinant XBB (and its sub-lineages) and 358 cases of BA.2.75 (or BA.2.75 sub-lineages) have been identified in Ireland.
- As of 29th November 2022, 68% of children aged 12-15 years have received their primary course of vaccination. Of those aged 5-11 years, 26% have received one dose of their primary course of vaccination.
- As of 29th November, approximately 36% of the population aged 50-64 years have received a second booster dose. For those aged 65 years and older, 78% have received a second booster dose and 36% have received a third booster dose.
- The HPSC has reported that influenza activity increased in Ireland during week 47 2022 (week ending 27th November 2022). Detections of influenza A(H3), A(H1)pdm09 and B have been reported this season to date. Respiratory syncytial virus (RSV) activity decreased during week 47 2022 but still remains at very high levels in Ireland. Given the increase in most influenza surveillance indicators, HPSC considers that influenza viruses are now circulating in Ireland. The number of influenza notifications increased during week 47 to 223, compared to 192 during week 46 (week ending 20th November 2022). During week 47 2022, 68 laboratory confirmed influenza cases were reported as hospital inpatients. This is stable compared to 65 laboratory confirmed influenza notifications reported as hospital inpatients during week 46 2022. One laboratory confirmed influenza case was admitted to critical care and notified to HPSC during week 47 2022. During weeks 40-47, 12 laboratory confirmed influenza cases have been admitted to critical care and notified to HPSC. In total, 611 RSV cases were notified during week 47, a decrease of 16%

compared to 731 during week 46. During week 47 2022, 53% of notified RSV cases were in the 0-4-year age group. There were 224 RSV hospitalised cases notified during week 47 2022, a decrease of 24% compared to 294 in week 46.

Outbreaks for week 47 (20th to 26th November) are based on those reported up to midnight on 26th November 2022.

There was a total of 46 COVID-19 outbreaks notified in week 47. Regional departments of public health are currently prioritising the reporting of outbreak investigations in settings that would benefit most from public health and clinical intervention.

Healthcare setting outbreaks:

- There were 16 new nursing home and 6 new community hospital/long-stay unit outbreaks reported in week 47. The case range of these outbreaks was 0-24 cases.
- There were 15 new acute hospital outbreaks reported in week 47, with a range of 0-10 cases.
- There were 7 new outbreaks reported in a residential institution setting (6 in centres for disabilities and 1 in centres for older people) in week 47, with 3-7 cases.
- There were 2 new outbreaks reported in 'other healthcare settings' (1 in clients of mental health facilities and 1 in other settings) in week 47, with 5-7 cases.

Noting that the national SARS-CoV-2 testing guidance may influence trends, the number of infections detected and reported daily (based on PCR and self-reported antigen tests) has increased over the last week. PCR testing volumes have been stable while test positivity has increased. A significant proportion of detected infections continues to be identified in older age groups.

The COVID-19 burden on acute hospital care remains significant. The total number of hospitalised COVID-19 cases has recently increased slightly and continues to be monitored (346 as of 2nd December). The daily average number of newly confirmed cases in hospital has also increased (52 per day observed in the seven days to 2nd December). Data for COVID-19 cases in hospital as of 29th November show that 38% were hospitalised for COVID-19 disease, with the remainder categorised as asymptomatic infectious cases.

The total number of confirmed cases in critical care (14 as of 2nd December) has been broadly stable. The number of ICU COVID-19 cases requiring mechanical ventilation has been stable. The proportion of cases whose primary reason for admission to ICU was COVID-19 was 25% as of 29th November. The number of COVID-19 patients in receipt of advanced respiratory support in hospital settings outside of ICU has been stable.

The number of notified outbreaks has been broadly stable across key vulnerable settings. COVID-19 mortality has remained broadly stable, although it is noted that there can be a lag in reporting of deaths.

You will be aware from colleagues in the Department that the acute hospital system remains under considerable pressure, with COVID-19 continuing to impact on acute capacity (346 COVID-19 inpatients on 2nd December).

We continue to closely monitor emerging SARS-CoV-2 variants and assess any potential threat to population health. The World Health Organization (WHO) is currently monitoring the global circulation of a number of Omicron variants including BQ.1 and its sublineages and XBB. WHO has reported (30th November 2022) that a comparison of sequences submitted to GISAID (genomic sequencing database) during weeks 44 (31st October to 6th November 2022) and 45 (7th to 13th November 2022) shows an increase from 23.1% to 27.3% for BQ.1 and its descendent lineages. As of 28 November, BQ.1 has over 30 descendent lineages. During the same period, the prevalence of XBB and its descendent lineages increased from 2.7% to 3.8%.

The European Centre for Disease Prevention and Control (ECDC) has reported that (1st December 2022), as of weeks 45 to 46 (7th November to 20th November 2022), BQ.1 has become the dominant variant in a number of EU/EEA countries but high prevalence of BQ.1 does not appear to be associated with a deterioration of the epidemiological situation. Some of the countries in which BQ.1 is dominant are among those showing recent increases in transmission and/or severity indicators, but the countries with the highest reported proportions of BQ.1 have not reported any concerning epidemiological changes to date.

The circulation of SARS-CoV-2 variants in Ireland continues to be closely monitored. As of 19th November 2022, the HPSC has reported that 967 cases of BQ.1 and its sub-lineages have been detected in Ireland through whole genome sequencing. BQ.1 variant (and its sub-lineages) has increased as a proportion of cases sequenced in Ireland. BQ.1 variant (including its lineages) represents in excess of 50% of reported sequenced cases with a specimen collection date in recent epidemiological weeks in Ireland. In addition, as of 19th November, 46 cases of Omicron recombinant XBB (and its sub-lineages) and 358 cases of BA.2.75 (or BA.2.75 sub-lineages) have been identified in Ireland.

In regard to the epidemiological situation in the European Union (EU)/European Economic Area (EEA), the ECDC has reported (1st December 2022) that, at the end of week 47 2022 (week ending 27th November), the pooled EU/EEA COVID-19 case rate in people aged 65 years and older continued to decrease, while the overall (all ages) COVID-19 case rate started to increase, up 5% compared to the previous week. Seven of the 28 countries with available data reported increases compared with the previous week in at least one of these indicators of transmission. These increases were recent (of 1–2 weeks duration), starting from relatively low levels. Pooled hospital or ICU admissions/occupancy remained stable at the EU/EEA level. However, increases were reported by seven of the 21 countries with data on these indicators. Increases were recent (of 1–3 weeks duration) and reported values relatively low.

In summary, the overall epidemiological situation in Ireland indicates that the number of reported and detected infections has increased. The total number of hospitalised COVID-19 cases and the daily average of newly confirmed cases in hospital have also slightly increased recently. The total number of confirmed cases in critical care has been broadly stable. SARS-CoV-2 variants (including BQ.1) continue to be closely monitored. As in a number of other European countries, the proportion of BQ.1 variant (and its sub-lineages) identified amongst cases sequenced in Ireland has increased. BQ.1 variant (including its lineages) represents in excess of 50% of reported sequenced cases with a specimen collection date in recent epidemiological weeks. The increase in circulation of BQ.1 (and its sub-lineages) in Ireland may contribute to an increase in COVID-19 cases and hospitalisations in the coming weeks and months.